Humanin

Humanin is a 24-amino-acid peptide encoded by a small open reading frame (ORF) embedded within the 16S ribosomal RNA gene of the mitochondrial genome, making it the founding member of the mitochondrial-derived peptide (MDP) family. It was first isolated in 2001 from surviving neurons in the occipital cortex of an Alzheimer's disease patient. Unlike nuclear-encoded proteins, humanin originates directly from mitochondrial DNA and is thought to function as a systemic signal of mitochondrial stress and cellular integrity.

Its cytoprotective activity proceeds through two major routes. Extracellularly, humanin binds the trimeric cytokine receptor complex comprising WSX-1, CNTF receptor-alpha, and gp130, thereby activating the STAT3 and ERK1/2 pro-survival cascades. It also engages formyl peptide receptors (FPRs), which may allow it to compete with amyloid-beta for receptor occupancy. Intracellularly, humanin binds directly to the pro-apoptotic proteins Bax and BimEL, blocking their translocation to the outer mitochondrial membrane and preventing cytochrome c and SMAC release.

Additional documented mechanisms include: • Activation of chaperone-mediated autophagy via lysosomal membrane association, directing oxidized proteins for degradation • Reduction of intracellular reactive oxygen species (ROS) • Binding to IGFBP-3, disrupting its interaction with importin-beta and modulating downstream insulin/IGF-1 signaling without altering IGF-1 binding affinity • Dose-dependent remodeling of fibrillar amyloid-beta (1-40) into non-toxic amorphous aggregates

Circulating humanin levels decline with age across mammalian species and are measurably reduced in Alzheimer's disease patients' cerebrospinal fluid and in cells harboring mitochondrial DNA mutations.

The most robust evidence for humanin derives from animal experiments and human observational biomarker data. No completed interventional therapeutic clinical trial in humans has been published as of mid-2026.

In aged rodent models, the potent HNG analog (S14G-humanin, approximately 1,000-fold more active than native humanin) was administered intraperitoneally at 4 mg/kg twice weekly for 14 months, beginning at 18 months of age in female C57BL/6N mice. Treatment significantly improved performance in Barnes maze and Y-maze cognitive tasks at 24-28 months. A separate study using the same dosing regimen documented prevention of age-related myocardial fibrosis, with reduced collagen deposition, attenuated profibrotic factor expression (including TGF-beta1 and FGF-2), and activation of the Akt/GSK-3beta cardioprotective pathway.

In Caenorhabditis elegans, transgenic overexpression of humanin extended mean lifespan from 17.7 to 19.0 days (approximately 7%) in a manner dependent on the daf-16/FOXO transcription factor, establishing a conserved link to insulin/IGF-1 signaling. Mid-life HNG treatment in mice reduced visceral fat and raised lean mass without extending maximum lifespan, suggesting healthspan rather than longevity extension.

Human evidence is confined to observational and epidemiological findings. Children of centenarians showed substantially elevated circulating humanin levels compared to age-matched controls. In the Health and Retirement Study (10,158 participants analyzed for cognitive outcomes from more than 15,600 genotyped), the mitochondrial SNP rs2854128 associated with a 14% reduction in circulating humanin and approximately two years of accelerated cognitive aging, particularly in African Americans. In the BVAIT cohort (75 African American and 75 Caucasian American adults), African Americans showed roughly 20% lower circulating humanin. CSF humanin was measurably decreased in Alzheimer's disease patients. In vitro, both humanin and HNG protected primary human skeletal myotubes from glucocorticoid-induced atrophy independently.

In chemotherapy models, co-administration of a humanin analog reversed bortezomib-induced bone growth arrest in mice while preserving anti-tumor efficacy, raising interest in its use as an adjunct cytoprotective agent. No human oncology trials have been completed.

Typical dosage: Research phase (research).

No therapeutic dosing protocol for humanin has been established through controlled clinical trials in humans. All dosing information below derives from published animal research or uncontrolled community self-administration reports and must be treated accordingly.

Published animal research: • HNG (S14G-humanin analog): 4 mg/kg intraperitoneally twice weekly in aged C57BL/6N mice. This dose sustained over 14 months produced measurable cardioprotective and cognitive benefits without reported organ toxicity in the preclinical model.

Allometric scaling from rodent to human (using standard body-surface-area conversion) would suggest an exploratory equivalent of approximately 280-400 mcg twice weekly for a 70 kg adult, though such calculations carry substantial uncertainty for peptide compounds and should not be used as a clinical guide.

Community self-administration reports (anecdotal, no clinical validation): • Native humanin: 1-5 mg subcutaneously once daily, in cycles of 4-12 weeks • HNG analog: 0.5-2 mg subcutaneously once daily, reflecting its roughly 1,000-fold greater potency versus native humanin

Humanin is not orally bioavailable due to rapid proteolytic degradation and requires parenteral (typically subcutaneous) administration. Native humanin and HNG are distinct compounds; substituting one for the other at equivalent doses is inappropriate and potentially hazardous.

This information is provided solely for educational purposes as a summary of published research and reported protocols. It does not constitute medical advice. Humanin is not approved by any regulatory authority for human therapeutic use, and its administration outside a supervised research setting carries unknown risks.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most formally studied combination is humanin alongside MOTS-c, another MDP encoded in the same mitochondrial 16S rRNA locus. A 2025 in vitro study in primary human skeletal myotubes demonstrated that both HNG and MOTS-c independently attenuated dexamethasone-induced atrophy, with each peptide acting through distinct signaling mechanisms (MOTS-c suppressed MURF1 upregulation and enhanced Akt phosphorylation; HNG preserved myotube area through separate pathways). Formal synergy between the two was not demonstrated in this study.

• MOTS-c: most studied companion; targets AMPK and glucose metabolism pathways; complementary rather than synergistic atrophy protection shown in vitro; no human co-administration data • SS-31 (elamipretide): targets cardiolipin on the inner mitochondrial membrane; theoretical complementarity with humanin's anti-apoptotic mitochondrial effects; no co-administration studies exist in any model; combination use in humans is anecdotal only • NAD+ precursors (NMN, NR): rationale based on overlapping support for mitochondrial biogenesis and energy metabolism; entirely anecdotal, with no published co-administration data involving humanin

All multi-agent combinations involving humanin in humans are anecdotal. No safety or efficacy data from controlled studies exist for any humanin-containing stack.

Humanin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Research phase. Safety profile being established

No formal human safety study of exogenous humanin administration has been conducted. The safety profile in humans is therefore unknown, and the following observations derive entirely from animal research and theoretical reasoning.

In published long-term rodent studies, twice-weekly intraperitoneal HNG injections at 4 mg/kg for 14 months produced no reported significant organ-level adverse effects. Preclinical acute toxicity testing has not identified lethal doses at concentrations up to 50 mg/kg in rodents, suggesting a wide margin in that model; this cannot be extrapolated to human safety without clinical data.

Key theoretical and preclinical concerns: • Anti-apoptotic risk: Humanin's inhibition of Bax and BimEL raises the theoretical concern that sustained pharmacological dosing could impair clearance of pre-malignant cells. Chemotherapy model data suggested humanin maintained anti-tumor cytotoxicity while protecting healthy tissue, which is somewhat reassuring, but cancer surveillance implications in chronically dosed humans have not been evaluated. • IGF-1 signaling perturbation: IGFBP-3 modulation could affect glucose homeostasis and tissue growth in ways not yet characterized. • Unknown pharmacokinetics: Half-life, volume of distribution, metabolite profile, and renal or hepatic clearance in humans have not been determined. • Injection site reactions: The most commonly reported adverse effects in community self-administration are mild, transient redness and swelling at the injection site; no systematic adverse event tracking exists.

Humanin is not FDA-approved and is not regulated as a drug or dietary supplement in the United States. It is available commercially only as a research compound. Individuals with active malignancy, significant cardiovascular disease, or metabolic disorders should regard exogenous humanin use as particularly high-risk given the complete absence of human safety data.